These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 20102486

  • 1. New oral antithrombotics: a need for laboratory monitoring. For.
    Mismetti P, Laporte S.
    J Thromb Haemost; 2010 Apr; 8(4):621-6. PubMed ID: 20102486
    [No Abstract] [Full Text] [Related]

  • 2. New oral antithrombotics: a need for laboratory monitoring. Against.
    Bounameaux H, Reber G.
    J Thromb Haemost; 2010 Apr; 8(4):627-30. PubMed ID: 20088926
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. New strategies for effective treatment of vitamin K antagonist-associated bleeding.
    Yates SG, Sarode R.
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S180-6. PubMed ID: 26149021
    [Abstract] [Full Text] [Related]

  • 6. Invited commentary.
    Henke PK.
    J Vasc Surg; 2010 Nov; 52(5):1270-1. PubMed ID: 21050988
    [No Abstract] [Full Text] [Related]

  • 7. Practice guidelines for reversal of new and old anticoagulants.
    Hartman SK, Teruya J.
    Dis Mon; 2012 Aug; 58(8):448-61. PubMed ID: 22818559
    [No Abstract] [Full Text] [Related]

  • 8. Do new oral anticoagulants require laboratory monitoring? The clinician point of view.
    Samama MM, Guinet C, Le Flem L.
    Thromb Res; 2012 Oct; 130 Suppl 1():S88-9. PubMed ID: 23026675
    [Abstract] [Full Text] [Related]

  • 9. Laboratory tests and the new oral anticoagulants.
    Tripodi A.
    Thromb Res; 2012 Oct; 130 Suppl 1():S95-7. PubMed ID: 23026677
    [Abstract] [Full Text] [Related]

  • 10. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.
    Garcia D, Barrett YC, Ramacciotti E, Weitz JI.
    J Thromb Haemost; 2013 Feb; 11(2):245-52. PubMed ID: 23216682
    [Abstract] [Full Text] [Related]

  • 11. Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.
    Arbit B, Hsu JC.
    Clin Cardiol; 2015 Nov; 38(11):684-91. PubMed ID: 26173428
    [Abstract] [Full Text] [Related]

  • 12. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr 11; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract] [Full Text] [Related]

  • 13. Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
    Prescrire Int; 2015 Jun 11; 24(161):150. PubMed ID: 26436165
    [Abstract] [Full Text] [Related]

  • 14. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
    Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, Koplan BA, McClennen S, Michaud GF.
    J Cardiovasc Electrophysiol; 2011 Mar 11; 22(3):248-54. PubMed ID: 20812929
    [Abstract] [Full Text] [Related]

  • 15. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
    Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
    J Thromb Haemost; 2013 Jan 11; 11(1):177-9. PubMed ID: 23419049
    [No Abstract] [Full Text] [Related]

  • 16. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?
    Le Gal G, Carrier M, Tierney S, Majeed H, Rodger M, Wells PS.
    J Thromb Haemost; 2010 Jan 11; 8(1):90-4. PubMed ID: 19874475
    [Abstract] [Full Text] [Related]

  • 17. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D, Chambefort V, Decousus H.
    Rev Prat; 2001 Sep 01; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract] [Full Text] [Related]

  • 18. The clinical implications of new oral anticoagulants: will the potential advantages be achieved?
    Phillips KW, Ansell J.
    Thromb Haemost; 2010 Jan 01; 103(1):34-9. PubMed ID: 20062925
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY, GLORIA-AF Investigators.
    Europace; 2016 Sep 01; 18(9):1308-18. PubMed ID: 27335063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.